Analyst Ranking
Bottom 4%
#4686 out of 4867 analysts
Average Return
-14.18%
Win Rate
31%22 out of 71
Risk vs Reward
Poor
Good

Paul Matteis's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Gw Pharmaceuticals PLCGWPH
+64.79%$98.51$162.33
2017-10-01 -
2018-10-02
Buy
Neurocrine Biosciences IncNBIX
+59.15%$72.78$115.83
2017-11-01 -
2018-11-02
Buy
Avadel Pharmaceuticals PLCAVDL
+53.86%$6.35$9.77
2020-03-11 -
2021-03-12
Strong Buy
Prevail Therapeutics IncPRVL
+51.12%$15.22$23.00
2020-07-15 -
2021-01-21
Strong Buy
Pepgen IncPEPG
+43.28%$12.20$17.48
2023-06-13 -
2024-06-13
Strong Buy

Paul Matteis Analyst Color

Get additional color on Paul Matteis's coverage of popular stocks

Paul Matteis's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Alnylam Pharmaceuticals IncALNY
8Strong Buy$345.00+34.14%Maintains
a month ago
Neumora Therapeutics IncNMRA
2Hold$2.00+160.76%Downgrades
2 months ago
Rhythm Pharmaceuticals IncRYTM
1Strong Buy$78.00+19.60%Reinstates
2 months ago
Sionna Therapeutics IncSION
1Strong Buy$32.00+165.78%Initiates Coverage On
2 months ago
Gh Research PLCGHRS
2Strong Buy$32.00+255.56%Maintains
2 months ago
Compass Pathways PLCCMPS
1Strong Buy$11.00+191.78%Initiates Coverage On
2 months ago
Vertex Pharmaceuticals IncVRTX
13Hold$494.00-1.89%Maintains
4 months ago
Uniqure NvQURE
1Strong Buy$32.00+130.88%Maintains
4 months ago
Sage Therapeutics IncSAGE
5Hold$6.00-21.05%Maintains
4 months ago
Denali Therapeutics IncDNLI
3Strong Buy$37.00+124.24%Upgrades
4 months ago
Alector IncALEC
5Hold$4.00+253.98%Downgrades
4 months ago
Alto Neuroscience IncANRO
3Strong Buy$10.00+309.84%Maintains
6 months ago
Neurogene IncNGNE
2Strong Buy$60.00+360.48%Maintains
6 months ago
Alkermes PLCALKS
5Strong Buy$36.00+25.13%Upgrades
6 months ago
Biomarin Pharmaceutical IncBMRN
8Strong Buy$87.00+37.48%Maintains
7 months ago
Dyne Therapeutics IncDYN
3Strong Buy$66.00+463.14%Maintains
8 months ago
Rapport Therapeutics IncRAPP
1Strong Buy$35.00+216.60%Initiates Coverage On
10 months ago
Ionis Pharmaceuticals IncIONS
4Hold$53.00+77.79%Maintains
10 months ago
Acadia Pharmaceuticals IncACAD
5Hold$21.00+45.53%Maintains
a year ago
Contineum Therapeutics IncCTNM
1Strong Buy$29.00N/AInitiates Coverage On
a year ago
Neurocrine Biosciences IncNBIX
5Strong Buy$144.00N/AMaintains
a year ago
Biogen IncBIIB
6Strong Buy$287.00N/AMaintains
a year ago
Lexeo Therapeutics IncLXEO
1Strong Buy$20.00N/AInitiates Coverage On
a year ago
Vistagen Therapeutics IncVTGN
1Strong Buy$12.00N/AInitiates Coverage On
a year ago
Pepgen IncPEPG
2Strong Buy$24.00N/AReiterates
2 years ago
Karuna Therapeutics IncKRTX
3Strong Buy$295.00N/AMaintains
3 years ago
Cerevel Therapeutics Holdings IncCERE
2Strong Buy$54.00N/AMaintains
3 years ago
Athira Pharma IncATHA
2Hold$5.00N/ADowngrades
3 years ago
Kalvista Pharmaceuticals IncKALV
1Strong Buy$32.00N/AMaintains
3 years ago
Vigil Neuroscience IncVIGL
1Strong Buy$24.00N/AInitiates Coverage On
3 years ago
Climb Bio IncCLYM
1Strong Buy$35.00N/AInitiates Coverage On
4 years ago
Acumen Pharmaceuticals IncABOS
1Strong Buy$27.00N/AInitiates Coverage On
4 years ago
Prevail Therapeutics IncPRVL
1Strong Buy$23.00N/AInitiates Coverage On
5 years ago
Gw Pharmaceuticals PLCGWPH
4Hold$140.00N/ADowngrades
5 years ago
Avadel Pharmaceuticals PLCAVDL
1Strong Buy$14.00N/AInitiates Coverage On
5 years ago
Zogenix IncZGNX
3Buy$60.00N/AInitiates Coverage On
6 years ago
Acorda Therapeutics IncACORQ
1Hold$2,280.00N/AMaintains
7 years ago
Akcea Therapeutics IncAKCA
2Hold$31.00N/AMaintains
7 years ago
Obseva SaOBSVF
1Buy$18.00N/AMaintains
7 years ago
Wave Life Sciences LtdWVE
1Buy$64.00N/AMaintains
7 years ago
Cidara Therapeutics IncCDTX
1Buy$340.00N/AInitiates Coverage On
8 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.